Trial Profile
Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2012
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications Cancer; Haematological malignancies
- Focus Pharmacokinetics
- Sponsors Cephalon
- 14 Feb 2012 Official title amended as reported by ClinicalTrials.gov.
- 01 Jun 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Jun 2010 as reported by ClinicalTrials.gov.